Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prayer sign as a marker of disease severity and treatment response in eosinophilic fasciitis: A case series.

JAAD case reports·2026

Same author

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides.

Experimental dermatology·2026

Same author

Modified Recommendations for the Radiation Dose in Patients with Mycosis Fungoides and Localized Lesional Disease Based on a Retrospective Analysis of Treatment Outcomes.

Practical radiation oncology·2025

Same author

IgM Immunohistochemical Expression is a Potential Risk Factor for Extracutaneous Dissemination in Patients With Primary Cutaneous Follicle Center Lymphoma.

The American journal of surgical pathology·2025

Same author

Incidence of γδ phenotype in mycosis fungoides: a prospective analysis.

The British journal of dermatology·2025

Same author

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms.

Blood neoplasia·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

[Moritz Kaposi and his sarcoma].

Anne van Kessel¹, Koen D Quint

¹Leids Universitair Medisch Centrum, afd. Huidziekten, Leiden, the Netherlands.

Nederlands Tijdschrift Voor Geneeskunde

|November 17, 2011

Summary

Kaposi sarcoma, initially described in 1872, is now understood as a complex, multidisciplinary condition. Increased insight into its etiology emerged following the HIV epidemic.

Area of Science:

Oncology
Dermatology
Infectious Diseases

Background:

Kaposi sarcoma was first identified in 1872 by dermatologist Moritz Kaposi as 'idiopathic multiple pigmented sarcoma of the skin'.
The condition was initially observed predominantly in men of Jewish or Mediterranean descent.
The name was officially changed to Kaposi sarcoma in 1912, a decade after Moritz Kaposi's passing.

Discussion:

Kaposi sarcoma is recognized today as a multidisciplinary condition, extending beyond dermatological observation.
The human immunodeficiency virus (HIV) epidemic significantly advanced the understanding of Kaposi sarcoma's etiology.
Ongoing research continues to explore the complex factors contributing to Kaposi sarcoma development.

Key Insights:

Kaposi sarcoma's historical context reveals its evolution from a rare skin condition to a complex disease.

More Related Videos

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

The HIV epidemic was a pivotal point in understanding the underlying causes of Kaposi sarcoma.

Multidisciplinary approaches are crucial for managing Kaposi sarcoma.

Outlook:

Further research into Kaposi sarcoma etiology is warranted.
Continued collaboration between oncologists, dermatologists, and infectious disease specialists will improve patient outcomes.
Advancements in understanding the human immunodeficiency virus (HIV) connection may lead to novel therapeutic strategies.